Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhuyun Liu

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Vaccine|May 17, 2018
The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4<sup>+</sup> T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathwaySonia Jain, Parakkal Jovvian George, Wanyan Deng, et al.
Plos Neglected Tropical Diseases|July 15, 2017
Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune responseJunfei Wei, Leroy Versteeg, Zhuyun Liu, et al.
Protein Expression and Purification|October 30, 2016
Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from Leishmania donovani, a vaccine candidate for preventing cutaneous leishmaniasisC Patrick McAtee, Christopher A Seid, Molly Hammond, et al.
Biorxiv : the Preprint Server for Biology|November 18, 2024
Mechanistic insights into structure-based design of a Lyme disease subunit vaccineKalvis Brangulis, Jill Malfetano, Ashley L Marcinkiewicz, et al.
Biorxiv : the Preprint Server for Biology|January 16, 2026
Develop a durable, memory-driven, CspZ-targeting Lyme disease vaccine by rationale adjuvant selectionMiranda McCarty, Sergio A Hernández, Jill Malfetano, et al.
NPJ Vaccines|May 16, 2026
Developing a durable, memory-driven, CspZ-targeting Lyme disease vaccine by rationale adjuvant selectionMiranda McCarty, Sergio A Hernández, Jill Malfetano, et al.
Human Vaccines & Immunotherapeutics|October 15, 2016
Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas diseaseChristopher A Seid, Kathryn M Jones, Jeroen Pollet, et al.
Nature Communications|April 6, 2025
Mechanistic insights into the structure-based design of a CspZ-targeting Lyme disease vaccineKalvis Brangulis, Jill Malfetano, Ashley L Marcinkiewicz, et al.
Vaccine|July 21, 2015
Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in miceViridiana Martinez-Campos, Pedro Martinez-Vega, Maria Jesus Ramirez-Sierra, et al.
Human Vaccines & Immunotherapeutics|February 4, 2016
Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic propertiesElissa M Hudspeth, Qian Wang, Christopher A Seid, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Vaccine|May 17, 2018
The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4<sup>+</sup> T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathwaySonia Jain, Parakkal Jovvian George, Wanyan Deng, et al.
Plos Neglected Tropical Diseases|July 15, 2017
Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune responseJunfei Wei, Leroy Versteeg, Zhuyun Liu, et al.
Protein Expression and Purification|October 30, 2016
Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from Leishmania donovani, a vaccine candidate for preventing cutaneous leishmaniasisC Patrick McAtee, Christopher A Seid, Molly Hammond, et al.
Biorxiv : the Preprint Server for Biology|November 18, 2024
Mechanistic insights into structure-based design of a Lyme disease subunit vaccineKalvis Brangulis, Jill Malfetano, Ashley L Marcinkiewicz, et al.
Biorxiv : the Preprint Server for Biology|January 16, 2026
Develop a durable, memory-driven, CspZ-targeting Lyme disease vaccine by rationale adjuvant selectionMiranda McCarty, Sergio A Hernández, Jill Malfetano, et al.
NPJ Vaccines|May 16, 2026
Developing a durable, memory-driven, CspZ-targeting Lyme disease vaccine by rationale adjuvant selectionMiranda McCarty, Sergio A Hernández, Jill Malfetano, et al.
Human Vaccines & Immunotherapeutics|October 15, 2016
Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas diseaseChristopher A Seid, Kathryn M Jones, Jeroen Pollet, et al.
Nature Communications|April 6, 2025
Mechanistic insights into the structure-based design of a CspZ-targeting Lyme disease vaccineKalvis Brangulis, Jill Malfetano, Ashley L Marcinkiewicz, et al.
Vaccine|July 21, 2015
Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in miceViridiana Martinez-Campos, Pedro Martinez-Vega, Maria Jesus Ramirez-Sierra, et al.
Human Vaccines & Immunotherapeutics|February 4, 2016
Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic propertiesElissa M Hudspeth, Qian Wang, Christopher A Seid, et al.
Pageof 7